PuSH - Publikationsserver des Helmholtz Zentrums München: Single dose hepatitis A immunisation: 7.5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Mayorga, O.* ; Bühler, S.* ; Jaeger, V.K.* ; Bally, S.* ; Hatz, C.* ; Frösner, G. ; Protzer, U. ; van Damme, P.* ; Egger, M.* ; Herzog, C.*

Single dose hepatitis A immunisation: 7.5 year observational pilot study in Nicaraguan children to assess protective effectiveness and humoral immune memory response.

J. Infect. Dis. 214, 1498-1506 (2016)

Verlagsversion

Postprint

DOI

PMC

	Open Access Green

Abstract
Metriken
Zusatzinfos

BACKGROUND: Universal two-dose hepatitis A virus (HAV) vaccination of toddlers effectively controls hepatitis A. High vaccine costs impede, however, implementation in endemic countries. To test single-dose vaccination as a possible alternative, we initiated an observational, longitudinal study in Nicaragua, to assess protective effectiveness and - through challenge vaccination - humoral immune memory response. METHODS: Following a 2003 serosurvey, 130 originally seronegative children received 2005 one dose virosomal HAV vaccine, followed by yearly serological and clinical assessments until 2012. After 7.5 years, a vaccine booster was administered. Concurrent antibody screening of patients presenting with hepatitis symptoms documented persistent HAV circulation in the communities studied. RESULTS: Between serosurvey and vaccination, 25 children contracted hepatitis A subclinically (>8,000 mIU/mL anti-HAV). In the remaining 105 children, immunisation resulted in 17-572 mIU/mL anti-HAV. Under the ≥15% annual infection risk, an estimated 60% of children were exposed to HAV encounters during follow-up. No child presented with hepatitis symptomatology. Serological breakthrough infection (7106 mIU/mL) was documented in one child, representing an estimated 98.3% (95%CI, 87.9-99.8) protective effectiveness. Boosting elicited an average 29.7-fold increase of anti-HAV levels. CONCLUSIONS: In children living in hyperendemic settings, one dose of virosomal HAV vaccine is sufficient to activate immune memory and may provide long-term protection.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

6.344

1.617